Danielle Harris

Danielle Harris is a Research Fellow at the Institute of Clinical Molecular Biology (IKMB) affiliated with Kiel University (CAU) and the University Medical Center Schleswig-Holstein (UKSH). Her work focuses on intestinal immunometabolism and microbiome therapeutics in the context of inflammatory bowel disease (IBD).

Her research explores the restoration of microbial tryptophan metabolism via enzyme inhibition and the development of microbiome-based treatments for IBD. She contributes to projects like Aden Phase 2 P7 and participates in collaborations with institutions such as the Research Center Borstel, HMGU, and the Max Planck Institute for Evolutionary Biology.

Currently, no scientific awards or publications are explicitly listed in the provided materials, but her involvement in DFG-funded research underscores her role in advancing IBD therapeutics.